Dencker S J, Malm U, Lepp M
Acta Psychiatr Scand. 1986 Feb;73(2):181-5. doi: 10.1111/j.1600-0447.1986.tb10584.x.
Thirty-two patients in remission were followed by regular ratings during a prospective neuroleptic withdrawal study. They were outpatients who fulfilled the DSM-III criteria of schizophrenia and who were motivated for drug withdrawal. The relapse rate was 81%. The results from the rating scales confirm the hypothesis that a symptom increase occurs before psychotic relapse. In the order statistical differences occurred, the factors predicting relapse were those concerned with positive psychopathology, motor dysfunction, impaired affects and sleep disturbances. The corresponding symptoms and signs were mainly concerned with thought disorders, paranoid ideation, overactivity, depression and insomnia middle, all of nonpsychotic degree of severity. If prodromes appear, the patient should resume his neuroleptic treatment, or other preventive measures should be taken. By such therapeutic interactions, psychotic relapse may be prevented, or can be dealt with in an outpatient setting.
在一项前瞻性抗精神病药物撤药研究中，对32名处于缓解期的患者进行了定期评估。他们是符合精神分裂症DSM-III标准且有撤药意愿的门诊患者。复发率为81%。评定量表的结果证实了精神病性复发前症状会增加的假设。在顺序统计差异出现时，预测复发的因素是那些与阳性精神病理学、运动功能障碍、情感受损和睡眠障碍有关的因素。相应的症状和体征主要涉及思维障碍、偏执观念、活动过多、抑郁和中度失眠，所有这些症状的严重程度均未达到精神病性程度。如果出现前驱症状，患者应恢复抗精神病药物治疗，或采取其他预防措施。通过这种治疗性干预，可以预防精神病性复发，或者在门诊环境中进行处理。
